Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (March 2019)

25 slides from Aerie Pharmaceuticals's investor presentation, Mar 12, 2019

  1. Slide 1: Company Overview Investor Presentation March 2019

    Company Overview Investor Presentation March 2019 Exhibit 99.1

  2. Slide 2: Important Information

    Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety

  3. Slide 3: Aerie Overview

    Aerie IOP–Reducing Products (IP 2030+) Pipeline Activities Rhopressa® – normal tension glaucoma, pseudo ex glaucoma, corneal healing... Retina Program – AR-13503 and AR-1105 (IND accepted Q1 2019) implants Sustained-Release Implant Manufacturing Platform Beyond Ophthalmology – potential for Aerie-ow

  4. Slide 4: Rhopressa®: Market Perspective

    Rhopressa®: Market Perspective Restated 2017 IQVIA U.S. Glaucoma Market = ~$2.8B Market, 34.6M TRx, 49M bottles Refer to the full Rhopressa® product label at www.rhopressa.com Rhopressa® has not been approved by any regulatory authority other than the FDA For Investor Use - ~$3B Market, 35M TRx, 52M

  5. Slide 5: Rhopressa® Formulary Coverage Increasing

    Rhopressa® Formulary Coverage Increasing For Investor Use As of 3/01/19: ~90% of Commercial Lives Covered ~40% Medicare Part D Lives Covered Q2 2019 Expect Majority Preferred Tier 2 Equivalent Coverage Commercial and Medicare Part D ------------Commercial------------- -----------Medicare Part D-----

  6. Slide 6: Rhopressa® U.S. Launch Update

    Rhopressa® U.S. Launch Update Weekly IQVIA Rx’s, IQVIA Bottles and Sales-Out Bottles: Actual Sales-Out to Pharmacies as of 3/1/19 Restated IQVIA data as of 3/1/19 *Actual bottles dispensed exceed Rx’s due to extended supply plans (e.g., 90 days’ supply) 9,644 5,839 7,460 Note: IQVIA reporting change

  7. Slide 7: Rhopressa® U.S. Launch Update

    Rhopressa® U.S. Launch Update For Investor Use Rhopressa® has not been approved by any regulatory authority other than the FDA. Strong Net Sales and Volume Growth: $130 net sales per unit $136 net sales per unit $122 net sales per unit FY 2018 Net Sales of $24.2 million meeting Guidance of $20 to $3

  8. Slide 8: Active Engagement at Key Conferences

    Active Engagement at Key Conferences American Glaucoma Society (AGS) March 2019 American Society of Cataract and Refractive Surgeons (ASCRS) April 2018 Association of Research in Vision and Ophthalmology (ARVO) April 2018 European Glaucoma Society (EGS) Florence, May 2018 European Society of Catarac

  9. Slide 9: Rocklatan™ Combination Product Candidate

    RocklatanTM (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Positioning as First Line Therapy: Benefits of Rhopressa® while also targeting the secondary drain Achieved statistical superiority to market-leading latanoprost At each of nine time points in each of the two Phase 3 trials If

  10. Slide 10: Rocklatan™ Efficacy and Safety

    RocklatanTM Efficacy and Safety Efficacy: RocklatanTM demonstrated statistical superiority over its components (market-leading PGA latanoprost and Rhopressa®) in Mercury 1 and 2 Phase 3 trials, at all measured time points Consistent incremental IOP-reduction over latanoprost and Rhopressa® in the ra

  11. Slide 11: Rocklatan™ Responder Analysis

    RocklatanTM Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 * ** *** ++Data on File Based on Mercury 1 Interim Analysis 2 For Investor Use

  12. Slide 12: Rocklatan™ Next Steps

    RocklatanTM Next Steps March 14, 2019 PDUFA Current U.S. sales force in final stages of training for RocklatanTM in advance of PDUFA Once FDA approved, Medicare Part D formulary submission to payers expected in April 2019 Commercial and Medicare Part D access expected to be accelerated in comparison

  13. Slide 13: Expanding Aerie Franchise: Europe and Japan

    Expanding Aerie Franchise: Europe and Japan Europe (2017 Europe “Big 5” Glaucoma Market: 91M units per year, 1.5X U.S. units) MAA accepted for Rhokiinsa® (Rhopressa®) in October 2018, expect 12-month review Mercury 3: 6-month safety and 90-day efficacy registration trial comparing RocklatanTM (known

  14. Slide 14: Europe Glaucoma Market

    Europe Glaucoma Market: Aerie Expects to Commercialize on Its Own (if approved) “Big 5” Europe Glaucoma Market – 2017 $1.0B; 91M TRx*, Market Share in TRx PGA: Prostaglandin Analogue; BB: Beta Blocker; AA: Alpha Agonist; CAI: Carbonic Anhydrase Inhibitor Sources: IQVIA Analytics Link at ex-manufactu

  15. Slide 15: Japan Glaucoma Market

    Japan Glaucoma Market: Aerie Expects to Partner for Commercialization (if approved) PGA: Prostaglandin Analogue; BB: Beta Blocker; AA: Alpha Agonist; CAI: Carbonic Anhydrase Inhibitor Sources: IQVIA Analytics Link at ex-manufacturer price level – March 2018. *TRx calculated from IQVIA unit data (1 m

  16. Slide 16: Advancing the Pipeline

    Advancing the Pipeline AR-13503 and AR-1105 are preclinical stage molecules and have not been approved by the FDA or any regulatory agency Additional potential Rhopressa® indications are being considered for further study and are not labeled indications. Rhopressa® Research Targets 24-hour IOP reduc

  17. Slide 17: Retinal Eye Diseases – Aerie's Next Chapter

    Retinal Eye Diseases – Aerie’s Next Chapter For Investor Use Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular

  18. Slide 18: 2018 U.S. Retinal Disease Market

    2018 U.S. Retinal Disease Market For Investor Use 2018 Sales: $6.0B 2018 Unit Sales: 7.3MM Sources: Mixture of public information, IQVIA, Market-Scope and estimates - March 2019

  19. Slide 19: Aerie's Innovation in Retinal Disease

    Aerie’s Innovation in Retinal Disease For Investor Use Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg Aerie Kinase Library Non-Aerie drug candidates AMD DME RVO Dry AMD/GA Glaucoma

  20. Slide 20: Retinal Eye Disease Unmet Needs in AMD and DME

    Retinal Eye Disease For Investor Use Unmet Needs in AMD and DME Need new treatments to address disease mechanisms beyond VEGF Complex pathology cannot be addressed by a single drug class Many patients do not achieve and/or maintain sufficient efficacy AMD: Anti-VEGF efficacy often lost after 5–7 yea

  21. Slide 21: Lead Retina Products

    Lead Retina Products For Investor Use AR-1105 (Dexamethasone) Implant Indications: retinal vein occlusion (RVO) and DME Target product profile vs. Ozurdex® Longer duration of efficacy (6 mo vs 3 mo) Improved administration due to smaller needle Potential for fewer adverse effects due to lower peak d

  22. Slide 22: AR-13503 Provides Efficacy Similar to Eylea® in PDR Model

    Oxygen-induced retinopathy (OIR) mouse model - PDR Administration: Intraperitoneal QD For Investor Use Preclinical AR-13503 Provides Efficacy Similar to Eylea® in a Proliferative Diabetic Retinopathy Model Vehicle (n=14) 1.25 mg/kg AR-13503 (n=16) 1 mg/kg Eylea (n=14) Data on File For more informati

  23. Slide 23: AR-13503 Synergistic to Eylea® in Mouse Model

    AR-13503 Synergistic to Eylea® in Mouse Model of Proliferative Diabetic Retinopathy Oxygen-induced retinopathy (OIR) mouse model - PDR -40% *** * Administration: Intraperitoneal QD * : p<0.01 *** : p<0.0001 For Investor Use -60% % of Total Area Neovascular Area (+SEM) Data on File Sub-optimal dose l

  24. Slide 24: Evaluating Aerie's 3,500+ Owned Molecules

    Evaluating Aerie’s 3,500+ Owned Molecules ROCK Commencing screening for additional indications beyond ophthalmology ROCK inhibition should have potential in: Pulmonary health, including pulmonary fibrosis and bronchial asthma Dermatology indications Cancer Others Relationship tree of human kinases.

  25. Slide 25: Summary Key Priorities

    Summary Key Priorities Rhopressa®: Continued successful launch execution RocklatanTM: U.S. PDUFA set for March 14, 2019 Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility Research Initiatives Rhopressa® 24-hour IOP reduction, normal tensio

Aerie Pharmaceuticals — Investor Presentation (March 2019) on 6ix